Showing results (131-140 of 152) with videos related to
Sort By:
Pageof 16
Lancet (London, England)|March 19, 2013
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trialKris V Kowdley, Eric Lawitz, Israel Crespo, et al.Lancet (London, England)|August 1, 2014
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised studyEric Lawitz, Mark S Sulkowski, Reem Ghalib, et al.The New England Journal of Medicine|November 17, 2015
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated CirrhosisMichael P Curry, Jacqueline G O'Leary, Natalie Bzowej, et al.Journal of Hepatology|January 11, 2025
AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trialsJavier Armisen, Mitra Rauschecker, Janeli Sarv, et al.The New England Journal of Medicine|June 24, 2011
Telaprevir for retreatment of HCV infectionStefan Zeuzem, Pietro Andreone, Stanislas Pol, et al.The New England Journal of Medicine|April 24, 2013
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment optionsIra M Jacobson, Stuart C Gordon, Kris V Kowdley, et al.Journal of Hepatology|December 24, 2013
Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null responseJohn M Vierling, Mitchell Davis, Steven Flamm, et al.Clinical Therapeutics|September 7, 2018
The Safety and Antiviral Activity of BZF961 with or without Ritonavir in Patients Infected with Hepatitis C Virus: A Randomized, Multicenter TrialEric Lawitz, Mohamed Bidair, Thomas Marbury, et al.The New England Journal of Medicine|January 17, 2014
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infectionMark S Sulkowski, David F Gardiner, Maribel Rodriguez-Torres, et al.Hepatology (Baltimore, Md.)|January 24, 2015
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III studyDavid R Nelson, James N Cooper, Jacob P Lalezari, et al.Pageof 16